학술저널
[종설] 2020년 FDA 승인 방사성 의약품
FDA Approved Radiopharmaceuticals in 2020
- 대한약학회
- 약학회지
- 제65권 제3호(2021년)
-
2021.06169 - 173 (5 pages)
-
DOI : 10.17480/psk.2021.65.3.169
- 152
Radiopharmaceuticals are radioactive isotopes and labeled compounds used to diagnose and treat diseases. The global radiopharmaceutical market is expected to grow at an average annual rate of 12.4%, reaching $14,728 million by 2023. Four of the 53 new drugs approved by the US FDA in 2020 are radiopharmaceuticals. All four radiopharmaceuticals are radioisotopelabeled diagnostics used in positron emission tomography (PET) imaging. This review describes four FDA-approved radiopharmaceuticals, including incorporated radioisotopes, target proteins, modes of action, and clinical indications.
서 론(Introduction)
본론: 미국 FDA 승인 방사성 의약품
결 론(Conclusion)
(0)
(0)